NCT01371305View on ClinicalTrials.gov

STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

July 16, 2012

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
DRUG

BG00011

BG00011 will be administered at varying doses via subcutaneous (SC) injection

DRUG

Placebo

Sterile normal saline (0.9% Sodium Chloride for Injection) via Subcutaneous (SC) injections.

Trial Locations (10)

15213

Research Site, Pittsburgh

30322

Research Site, Atlanta

37232

Research Site, Nashville

44195

Research Site, Cleveland

66160

Research Site, Kansas City

77030

Research Site, Houston

94143

Research Site, San Francisco

02114

Research Site, Boston

02115

Research Site, Boston

03756

Research Site, Lebanon

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY